Documented use of BPC-157, the unapproved synthetic peptide nicknamed the "Wolverine" peptide, rose 33-fold between 2020 and 2026, according to a new analysis of clinical notes covering more than 1,000 patients. The FDA has not approved it for any indication.

BPC-157 is marketed directly to consumers for pain relief, tissue healing, and performance enhancement. Because it carries no National Drug Code and cannot be tracked like a prescription drug, researchers at the data analytics firm nference searched more than 15 million medical records for mentions of the compound, then used large language models validated by physician review to confirm actual use in the notes.

Who is using it

Of 1,536 patients whose notes mentioned BPC-157, 1,039 had documented use, and newly confirmed users climbed from 4 in the first quarter of 2020 to 134 in the first quarter of 2026. The user profile shifted along the way: the male share rose from 57% to 70%, and mean age fell from 55 to 49.

Among the 644 patients with a documented reason for use, pain led at 33%, followed by gastrointestinal conditions such as reflux, inflammatory bowel disease or gastritis at 14%, prior injury at 11%, and post-surgical healing at 10%. Of the 205 users with a documented supply source, 36% went through a compounding pharmacy and 35% through a gray-market peptide vendor, which is about as even a split between the regulated and unregulated channels as you will see in print.

Why the 79% figure proves little

Only 354 of the 1,039 confirmed users had any directional response recorded, and 79% of those reported improvement. That number will be quoted everywhere, and it should not be.

Flynn McGuire, MD, of the University of Utah, who studies BPC-157 but was not involved in the analysis, noted that roughly half the documented users were also taking other drugs or undergoing physical therapy or surgery. The analysis had no placebo or untreated comparison group, no standardized dose or formulation, and no consistent outcome measurement, making it impossible to attribute any improvement specifically to BPC-157.

Safety signals and the compounding decision

When discontinuation was documented, clinician advice was the most common reason, followed by adverse events including neuropsychiatric, dermatologic and gastrointestinal symptoms. The FDA's Adverse Event Reporting System has logged 10 serious adverse event reports tied to BPC-157 since 2021, 8 of them in 2026 alone, though the agency notes such reports do not establish causation.

Study leader Venky Soundararajan, PhD, cautioned that most physicians are not systematically asking patients about BPC-157, so the true scope of use is likely undercounted. The findings land while the FDA weighs whether to permit pharmacy compounding of the peptide, a shift an advisory panel endorsed in July with HHS Secretary Robert F. Kennedy Jr's encouragement.

Bottom line

The agency had previously restricted compounding over safety concerns and has not issued a final decision. What this analysis establishes is demand, not effect, and the gap between the two is the entire story.